Senior living provider Brookdale Senior Living (NYSE:BKD) missed Wall Street's revenue expectations in Q2 CY2026, with sales falling 11.6% year on year to $718.6 million. Its GAAP profit of $0.10 per share was significantly above analysts' consensus estimates.
Is now the time to buy Brookdale? Find out in our full research report .
Brookdale (BKD) Q2 CY2026 Highlights:
-
Revenue:$718.6 million vs analyst estimates of $735.7 million (11.6% year-on-year decline, 2.3% miss)
-
EPS (GAAP):$0.10 vs analyst estimates of -$0.06 (significant beat)
-
Adjusted EBITDA:$122.1 million vs analyst estimates of $121.3 million (17% margin, 0.6% beat)
-
EBITDA guidance for the full yearis $509 million at the midpoint, in line with analyst expectations
-
Operating Margin:11.9%, up from 1.8% in the same quarter last year
-
Free Cash Flow Margin:6.1%, up from 3.6% in the same quarter last year
-
Market Capitalization:$3.40 billion
"We continue to execute on our strategy to optimize Brookdale's operating performance and real estate portfolio for the immense senior housing opportunity ahead of us as the baby boom generation begins to reach age 80," said Nick Stengle, Brookdale's Chief Executive Officer.
Company Overview
With a network of over 650 communities serving approximately 59,000 residents across 41 states, Brookdale Senior Living (NYSE:BKD) operates senior living communities across the United States, offering independent living, assisted living, memory care, and continuing care retirement communities.
Revenue Growth
A company's long-term performance is an indicator of its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Unfortunately, Brookdale struggled to consistently increase demand as its $3.05 billion of sales for the trailing 12 months was close to its revenue five years ago. This wasn't a great result and is a sign of lacking business quality.
We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Just like its five-year trend, Brookdale's revenue over the last two years was flat, suggesting it is in a slump.
This quarter, Brookdale missed Wall Street's estimates and reported a rather uninspiring 11.6% year-on-year revenue decline, generating $718.6 million of revenue.
Looking ahead, sell-side analysts expect revenue to decline by 1.9% over the next 12 months, a slight deceleration versus the last two years. This projection is underwhelming and suggests its products and services will see some demand headwinds.
WHILE YOU'RE HERE: The Next Palantir?One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You've probably never heard of it.
This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE .
Adjusted Operating Margin
Brookdale was profitable over the last five years but held back by its large cost base. Its average adjusted operating margin of 1.5% was weak for a healthcare business.
On the plus side, Brookdale's adjusted operating margin rose by 12.3 percentage points over the last five years. Zooming in on its more recent performance, we can see the company's trajectory is intact as its margin has also increased by 4.4 percentage points on a two-year basis.
In Q2, Brookdale generated an adjusted operating margin profit margin of 12.4%, up 8.8 percentage points year on year. This increase was a welcome development, especially since its revenue fell, showing it was more efficient because it scaled down its expenses.
Earnings Per Share
Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth — for example, a company could inflate its sales through excessive spending on advertising and promotions.
Although Brookdale's full-year earnings are still negative, it reduced its losses and improved its EPS by 21.6% annually over the last five years. The next few quarters will be critical for assessing its long-term profitability.
In Q2, Brookdale reported EPS of $0.10, up from negative $0.18 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Brookdale to improve its earnings losses. Analysts forecast its full-year EPS will improve from negative $0.58 to negative $0.02.
Key Takeaways from Brookdale's Q2 Results
It was good to see Brookdale beat analysts' EPS expectations this quarter. On the other hand, its revenue missed. Looking ahead, full-year EBITDA guidance was in line. Overall, this quarter was mixed. The stock traded up 1.4% to $13.91 immediately after reporting.
Is Brookdale an attractive investment opportunity at the current price? If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free .
